Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
Year: 2018
Type: article
Study design: Clinical Trial
Source: Gastroenterology
Authors: Stephen A. Harrison, Manal F. Abdelmalek, Stephen Caldwell, Mitchell L. Shiffman, Anna Mae Diehl, Reem Ghalib, Eric J. Lawitz, Don C. Rockey, Raul Aguilar Schall, Catherine Jia, Bryan J. McColgan, John G. McHutchison, G. Mani Subramanian, Robert P. Myers, Zobair Younossi, Vlad Ratziu, Andrew J. Muir, Nezam H. Afdhal, Zachary Goodman, Jaime Bosch, Arun J. Sanyal
Institutions: Pinnacle Clinical Research, Duke University, University of Virginia, The University of Texas at San Antonio Health Science Center, Texas Liver Institute, Medical University of South Carolina, Gilead Sciences (United States), Inova Fairfax Hospital, Beth Israel Deaconess Medical Center, Harvard University, Pitié-Salpêtrière Hospital, University of Bern, University Hospital of Bern, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, Virginia Commonwealth University
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Gilead Sciences, FibroGen
OpenAlex ID: W2821544409